IPHA (Innate Pharma) Total Assets : $116.29 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Total Assets?

Innate Pharma's Total Assets for the quarter that ended in Dec. 2024 was $116.29 Mil.

During the past 12 months, Innate Pharma's average Total Assets Growth Rate was -67.00% per year. During the past 3 years, the average Total Assets Growth Rate was -41.00% per year. During the past 5 years, the average Total Assets Growth Rate was -26.80% per year. During the past 10 years, the average Total Assets Growth Rate was 2.80% per year.

During the past 13 years, Innate Pharma's highest 3-Year average Total Assets Growth Rate was 86.40%. The lowest was -41.00%. And the median was 3.90%.

Total Assets is connected with ROA %. Innate Pharma's annualized ROA % for the quarter that ended in Dec. 2024 was -37.04%. Total Assets is also linked to Revenue through Asset Turnover. Innate Pharma's Asset Turnover for the quarter that ended in Dec. 2024 was 0.03.

Innate Pharma Total Assets Historical Data

The historical data trend for Innate Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Total Assets Chart

Innate Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

373.99

302.26

220.19

200.87

116.29

Innate Pharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Assets	Get a 7-Day Free Trial															220.19	215.65	200.87	163.08	116.29

Innate Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Innate Pharma's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	9.25	+	107.042
	=	116.29

Innate Pharma's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	9.25	+	107.042
	=	116.29

Innate Pharma (NAS:IPHA) Total Assets Explanation

Total Assets is connected with ROA %.

Innate Pharma's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-51.742	/	( (163.075	+	116.292)	/ 2 )
	=	-51.742	/	139.6835
	=	-37.04 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Innate Pharma's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	4.545	/	( (163.075	+	116.292)	/ 2 )
=	4.545	/	139.6835
=	0.03

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Innate Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

0EVI:UK IPH:France IDD:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.